225 related articles for article (PubMed ID: 17885675)
21. SIRT1-NOX4 signaling axis regulates cancer cachexia.
Dasgupta A; Shukla SK; Vernucci E; King RJ; Abrego J; Mulder SE; Mullen NJ; Graves G; Buettner K; Thakur R; Murthy D; Attri KS; Wang D; Chaika NV; Pacheco CG; Rai I; Engle DD; Grandgenett PM; Punsoni M; Reames BN; Teoh-Fitzgerald M; Oberley-Deegan R; Yu F; Klute KA; Hollingsworth MA; Zimmerman MC; Mehla K; Sadoshima J; Tuveson DA; Singh PK
J Exp Med; 2020 Jul; 217(7):. PubMed ID: 32441762
[TBL] [Abstract][Full Text] [Related]
22. Wnt/β-Catenin Signaling Contributes to Skeletal Myopathy in Heart Failure via Direct Interaction With Forkhead Box O.
Okada K; Naito AT; Higo T; Nakagawa A; Shibamoto M; Sakai T; Hashimoto A; Kuramoto Y; Sumida T; Nomura S; Ito M; Yamaguchi T; Oka T; Akazawa H; Lee JK; Morimoto S; Sakata Y; Shiojima I; Komuro I
Circ Heart Fail; 2015 Jul; 8(4):799-808. PubMed ID: 26038536
[TBL] [Abstract][Full Text] [Related]
23. Magnolol inhibits myotube atrophy induced by cancer cachexia through myostatin signaling pathway in vitro.
Ge Z; Liu D; Shang Y; Li Y; Chen SZ
J Nat Med; 2020 Sep; 74(4):741-749. PubMed ID: 32601830
[TBL] [Abstract][Full Text] [Related]
24. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia.
Fukawa T; Yan-Jiang BC; Min-Wen JC; Jun-Hao ET; Huang D; Qian CN; Ong P; Li Z; Chen S; Mak SY; Lim WJ; Kanayama HO; Mohan RE; Wang RR; Lai JH; Chua C; Ong HS; Tan KK; Ho YS; Tan IB; Teh BT; Shyh-Chang N
Nat Med; 2016 Jun; 22(6):666-71. PubMed ID: 27135739
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness.
Chacon-Cabrera A; Fermoselle C; Urtreger AJ; Mateu-Jimenez M; Diament MJ; de Kier Joffé ED; Sandri M; Barreiro E
J Cell Physiol; 2014 Nov; 229(11):1660-72. PubMed ID: 24615622
[TBL] [Abstract][Full Text] [Related]
26. Investigation of niclosamide as a repurposing agent for skeletal muscle atrophy.
Kim HJ; Lee JH; Kim SW; Lee SH; Jung DW; Williams DR
PLoS One; 2021; 16(5):e0252135. PubMed ID: 34038481
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model.
Hanada K; Fukasawa K; Hinata H; Imai S; Takayama K; Hirai H; Ohfusa R; Hayashi Y; Itoh F
Cancer Sci; 2022 Oct; 113(10):3547-3557. PubMed ID: 35849084
[TBL] [Abstract][Full Text] [Related]
28. Modulation of melanocortin signaling ameliorates uremic cachexia.
Cheung WW; Rosengren S; Boyle DL; Mak RH
Kidney Int; 2008 Jul; 74(2):180-6. PubMed ID: 18432186
[TBL] [Abstract][Full Text] [Related]
29. FOXO1 cooperates with C/EBPδ and ATF4 to regulate skeletal muscle atrophy transcriptional program during fasting.
Oyabu M; Takigawa K; Mizutani S; Hatazawa Y; Fujita M; Ohira Y; Sugimoto T; Suzuki O; Tsuchiya K; Suganami T; Ogawa Y; Ishihara K; Miura S; Kamei Y
FASEB J; 2022 Feb; 36(2):e22152. PubMed ID: 35061305
[TBL] [Abstract][Full Text] [Related]
30. cAMP-dependent protein kinase inhibits FoxO activity and regulates skeletal muscle plasticity in mice.
Silveira WA; Gonçalves DA; Machado J; Lautherbach N; Lustrino D; Paula-Gomes S; Pereira MG; Miyabara EH; Sandri M; Kettelhut IC; Navegantes LC
FASEB J; 2020 Sep; 34(9):12946-12962. PubMed ID: 32772437
[TBL] [Abstract][Full Text] [Related]
31. Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL-6/STAT3/FoxO signaling pathway.
Wang Y; Sun X; Yang Q; Guo C
Phytother Res; 2023 Aug; 37(8):3380-3393. PubMed ID: 37073890
[TBL] [Abstract][Full Text] [Related]
32. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
33. Muscle wasting in cancer.
Johns N; Stephens NA; Fearon KC
Int J Biochem Cell Biol; 2013 Oct; 45(10):2215-29. PubMed ID: 23770121
[TBL] [Abstract][Full Text] [Related]
34. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
[TBL] [Abstract][Full Text] [Related]
35. Myostatin and MyoD family expression in skeletal muscle of IGF-1 knockout mice.
Miyake M; Hayashi S; Sato T; Taketa Y; Watanabe K; Hayashi S; Tanaka S; Ohwada S; Aso H; Yamaguchi T
Cell Biol Int; 2007 Oct; 31(10):1274-9. PubMed ID: 17590360
[TBL] [Abstract][Full Text] [Related]
36. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.
Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F
Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375
[TBL] [Abstract][Full Text] [Related]
37. FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness.
Neyroud D; Nosacka RL; Callaway CS; Trevino JG; Hu H; Judge SM; Judge AR
J Cachexia Sarcopenia Muscle; 2021 Apr; 12(2):421-442. PubMed ID: 33527776
[TBL] [Abstract][Full Text] [Related]
38. FoxO Transcription Factors Are Critical Regulators of Diabetes-Related Muscle Atrophy.
O'Neill BT; Bhardwaj G; Penniman CM; Krumpoch MT; Suarez Beltran PA; Klaus K; Poro K; Li M; Pan H; Dreyfuss JM; Nair KS; Kahn CR
Diabetes; 2019 Mar; 68(3):556-570. PubMed ID: 30523026
[TBL] [Abstract][Full Text] [Related]
39. Impaired regeneration: A role for the muscle microenvironment in cancer cachexia.
Talbert EE; Guttridge DC
Semin Cell Dev Biol; 2016 Jun; 54():82-91. PubMed ID: 26385617
[TBL] [Abstract][Full Text] [Related]
40. Targeting myostatin for therapies against muscle-wasting disorders.
Tsuchida K
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):487-94. PubMed ID: 18600566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
